Project Details
Description
A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy
| Status | Active |
|---|---|
| Effective start/end date | 10/1/22 → 10/1/24 |
Funding
- Vertex Pharmaceuticals Incorporated
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.